What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

World Journal of Gastroenterology

Volumn 19, Issue 33, 2013, Pages 5402-5420

  Scalera, Antonella ^a   Di Minno, Matteo Nicola Dario ^a   Tarantino, Giovanni ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Cancer Research Center of Mercogliano   (Italy)

Author keywords

Cytokines; Irritable bowel syndrome; Low grade chronic inflammation; Non alcoholic fatty liver disease

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; FATTY ACID; GAMMA INTERFERON; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; METFORMIN; PROBIOTIC AGENT; SEROTONIN 3 ANTAGONIST; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE DYSREGULATION; IMMUNITY; INTESTINE FLORA; INTESTINE MOTILITY; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; LIVER METABOLISM; MOOD DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; REVIEW; TH17 CELL;

CYTOKINES; IRRITABLE BOWEL SYNDROME; LOW GRADE CHRONIC INFLAMMATION; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; CENTRAL NERVOUS SYSTEM; FATTY LIVER; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; MICROBIOTA; OBESITY;

EID: 84883524717     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i33.5402     Document Type: Review

References (254)

1. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005; 22: 1129-1133 [PMID: 16108837 DOI: 10.1111/j.1464-5491.2005.01748.x]
2. Delgado-Aros S, Locke GR, Camilleri M, Talley NJ, Fett S, Zinsmeister AR, Melton LJ. Obesity is associated with increased risk of gastrointestinal symptoms: a populationbased study. Am J Gastroenterol 2004; 99: 1801-1806 [PMID: 15330922 DOI: 10.1111/j.1572-0241.2004.30887.x]
3. Talley NJ, Quan C, Jones MP, Horowitz M. Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. Neurogastroenterol Motil 2004; 16: 413-419 [PMID: 15305996 DOI: 10.1111/ j.1365-2982.2004.00530.x]
4. Sadik R, Björnsson E, Simrén M. The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2010; 22: 102-108 [PMID: 19701093 DOI: 10.1097/MEG.0b013e32832ffd9b]
5. Cremonini F, Camilleri M, Clark MM, Beebe TJ, Locke GR, Zinsmeister AR, Herrick LM, Talley NJ. Associations among binge eating behavior patterns and gastrointestinal symptoms: a population-based study. Int J Obes (Lond) 2009; 33: 342-353 [PMID: 19139750 DOI: 10.1038/ijo.2008.272]
6. Clements RH, Gonzalez QH, Foster A, Richards WO, Mc-Dowell J, Bondora A, Laws HL. Gastrointestinal symptoms are more intense in morbidly obese patients and are improved with laparoscopic Roux-en-Y gastric bypass. Obes Surg 2003; 13: 610-614 [PMID: 12935364 DOI: 10.1381/09608 9203322190835]
7. Bures J, Cyrany J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J, Vorisek V, Kopacova M. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010; 16: 2978-2990 [PMID: 20572300 DOI: 10.3748/wjg.v16.i24.2978]
8. Tarantino G, Colicchio P, Conca P, Finelli C, Di Minno MN, Tarantino M, Capone D, Pasanisi F. Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? J Inflamm (Lond) 2009; 6: 6 [PMID: 19291292 DOI: 10.1186/1476-9255-6-6]
9. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010; 25: 672-690 [PMID: 20492324 DOI: 10.1111/j.1440-1746.2010.06253.x]
10. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102]
11. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin Biochem 2005; 38: 203-217 [PMID: 15708540 DOI: 10.1016/j.clinbiochem.20 04.10.014]
12. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001]
13. Tarantino G, Savastano S, Colao A. Hepatic steatosis, lowgrade chronic inflammation and hormone/growth factor/ adipokine imbalance. World J Gastroenterol 2010; 16: 4773-4783 [PMID: 20939105 DOI: 10.3748/wjg.v16.i38.4773]
14. Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Cartenì M, Nardone G. Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012; 22: 471-476 [PMID: 22546554 DOI: 10.1016/j.numecd.2012.02.007]
15. Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 2012; 11: 440-449 [PMID: 22700625]
16. Ringel Y, Ringel-Kulka T. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J Clin Gastroenterol 2011; 45 Suppl: S145-S148 [PMID: 21992954]
17. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl 1: S1-S35 [PMID: 19521341 DOI: 10.1038/ajg.2008.122]
18. Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117: 636-647 [PMID: 17304351 DOI: 10.1172/JCI29255]
19. Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett NW, Grundy D, Corinaldesi R. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37 [PMID: 17241857 DOI: 10.1053/j.gastro.2006.11.039]
20. Gecse K, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztóczy A, Izbéki F, Fioramonti J, Wittmann T, Bueno L. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008; 57: 591-599 [PMID: 18194983 DOI: 10.1136/gut.2007.140210]
21. Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini V, Cremon C, Zeller F, Langer R, Daniel H, Michel K, Schemann M. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137: 1425-1434 [PMID: 19596012 DOI: 10.1053/j.gastro.2009.07.005]
22. Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP, Neunlist M. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201 [PMID: 18824556 DOI: 10.1136/gut.2007.140806]
23. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20 Suppl 2: 1-9 [PMID: 15335408 DOI: 10.1111/ j.1365-2036.2004.02036.x]
24. Nessim SJ, Komenda P, Rigatto C, Verrelli M, Sood MM. Frequency and microbiology of peritonitis and exit-site infection among obese peritoneal dialysis patients. Perit Dial Int 2012; 33: 167-174 [PMID: 22942268]
25. Paiva LV, Nomura RM, Dias MC, Zugaib M. Maternal obesity in high-risk pregnancies and postpartum infectious complications. Rev Assoc Med Bras 2012; 58: 453-458 [PMID: 22930024 DOI: 10.1016/S0104-4230(12)70228-2]
26. Easterbrook JD, Dunfee RL, Schwartzman LM, Jagger BW, Sandouk A, Kash JC, Memoli MJ, Taubenberger JK. Obese mice have increased morbidity and mortality compared to non-obese mice during infection with the 2009 pandemic H1N1 influenza virus. Influenza Other Respi Viruses 2011; 5: 418-425 [PMID: 21668672 DOI: 10.1111/ j.1750-2659.2011.00254.x]
27. Kerkhoffs GM, Servien E, Dunn W, Dahm D, Bramer JA, Haverkamp D. The influence of obesity on the complication rate and outcome of total knee arthroplasty: a meta-analysis and systematic literature review. J Bone Joint Surg Am 2012; 94: 1839-1844 [PMID: 23079875 DOI: 10.2106/JBJS.K.00820]
28. Dowsey MM, Choong PF. Obesity is a major risk factor for prosthetic infection after primary hip arthroplasty. Clin Orthop Relat Res 2008; 466: 153-158 [PMID: 18196388 DOI: 10.1007/s11999-007-0016-3]
29. Dorner TE, Schwarz F, Kranz A, Freidl W, Rieder A, Gisinger C. Body mass index and the risk of infections in institutionalised geriatric patients. Br J Nutr 2010; 103: 1830-1835 [PMID: 20205963 DOI: 10.1017/S0007114510000152]
30. Federico A, D'Aiuto E, Borriello F, Barra G, Gravina AG, Romano M, De Palma R. Fat: a matter of disturbance for the immune system. World J Gastroenterol 2010; 16: 4762-4772 [PMID: 20939104 DOI: 10.3748/wjg.v16.i38.4762]
31. Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A, Tarantino M, Scopacasa F, Vecchione R. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 2009; 21: 504-511 [PMID: 19318968 DOI: 10.1097/MEG.0b013e3283229b40]
32. Barbato A, Iacone R, Tarantino G, Russo O, Sorrentino P, Avallone S, Galletti F, Farinaro E, Della Valle E, Strazzullo P. Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. Intern Emerg Med 2009; 4: 315-323 [PMID: 19350365 DOI: 10.1007/s11739-009-0240-9]
33. Stanton MC, Chen SC, Jackson JV, Rojas-Triana A, Kinsley D, Cui L, Fine JS, Greenfeder S, Bober LA, Jenh CH. Inflammatory Signals shift from adipose to liver during high fat feeding and influence the development of steatohepatitis in mice. J Inflamm (Lond) 2011; 8: 8 [PMID: 21410952 DOI: 10.1186/1476-9255-8-8]
34. Wolowczuk I, Verwaerde C, Viltart O, Delanoye A, Delacre M, Pot B, Grangette C. Feeding our immune system: impact on metabolism. Clin Dev Immunol 2008; 2008: 639803 [PMID: 18350123 DOI: 10.1155/2008/639803]
35. Lamas O, Martínez JA, Marti A. Energy restriction restores the impaired immune response in overweight (cafeteria) rats. J Nutr Biochem 2004; 15: 418-425 [PMID: 15219927 DOI: 10.1016/j.jnutbio.2004.02.003]
36. Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, Wedemeyer I, Marquitan G, Gieseler RK, Baba HA, Gerken G, Canbay A. Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology 2010; 51: 92-102 [PMID: 19998387 DOI: 10.1002/ hep.23253]
37. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006; 130: 435-452 [PMID: 16472598 DOI: 10.1053/j.gastro.2005.10.055]
38. Jeong WI, Park O, Radaeva S, Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 2006; 44: 1441-1451 [PMID: 17133483 DOI: 10.1002/hep.21419]
39. Safadi R, Friedman SL. Hepatic fibrosis-role of hepatic stellate cell activation. MedGenMed 2002; 4: 27 [PMID: 12466770]
40. Jeong WI, Park O, Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology 2008; 134: 248-258 [PMID: 18166357 DOI: 10.1053/ j.gastro.2007.09.034]
41. Guebre-Xabier M, Yang S, Lin HZ, Schwenk R, Krzych U, Diehl AM. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 2000; 31: 633-640 [PMID: 10706553 DOI: 10.1002/hep.510310313]
42. Li Z, Soloski MJ, Diehl AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005; 42: 880-885 [PMID: 16175608 DOI: 10.1002/hep.20826]
43. Kremer M, Thomas E, Milton RJ, Perry AW, van Rooijen N, Wheeler MD, Zacks S, Fried M, Rippe RA, Hines IN. Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology 2010; 51: 130-141 [PMID: 20034047 DOI: 10.1002/hep.23292]
44. Maina V, Sutti S, Locatelli I, Vidali M, Mombello C, Bozzola C, Albano E. Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clin Sci (Lond) 2012; 122: 545-553 [PMID: 22142284 DOI: 10.1042/ CS20110366]
45. Li Z, Oben JA, Yang S, Lin H, Stafford EA, Soloski MJ, Thomas SA, Diehl AM. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 2004; 40: 434-441 [PMID: 15368448 DOI: 10.1002/hep.20320]
46. Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol 2009; 9: 883-889 [PMID: 19935807 DOI: 10.1038/nri2660]
47. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517 [PMID: 19132915 DOI: 10.1146/annurev.immunol.021908.132710]
48. Ma X, Hua J, Mohamood AR, Hamad AR, Ravi R, Li Z. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology 2007; 46: 1519-1529 [PMID: 17661402 DOI: 10.1002/hep.21823]
49. Tang Y, Bian Z, Zhao L, Liu Y, Liang S, Wang Q, Han X, Peng Y, Chen X, Shen L, Qiu D, Li Z, Ma X. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol 2011; 166: 281-290 [PMID: 21985374 DOI: 10.1111/j.1365-2249.2011.04471.x]
50. Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002; 282: G1-G5 [PMID: 11751151]
51. Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 2007; 22: 491-497 [PMID: 17376039 DOI: 10.1111/ j.1440-1746.2006.04758.x]
52. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614 [PMID: 9335502 DOI: 10.1038/39335]
53. Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Ustundag B. The treatment with antibody of TNFalpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine-and choline-deficient diet. Inflammation 2008; 31: 91-98 [PMID: 18066656 DOI: 10.1007/s10753-007-9053-z]
54. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998; 83: 2907-2910 [PMID: 9709967 DOI: 10.1210/ jc.83.8.2907]
55. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54 [PMID: 15239085 DOI: 10.1002/hep.20280]
56. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-280 [PMID: 11832442 DOI: 10.1053/gast.2002.31065]
57. Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, De Munter S, Prawitt J, Caron S, Staels B, Van Vlierberghe H, Van Gaal L, Geerts A. Evaluation of inflammatory and angiogenic factors in patients with nonalcoholic fatty liver disease. Cytokine 2012; 59: 442-449 [PMID: 22658783 DOI: 10.1016/j.cyto.2012.05.001]
58. Kitamura K, Nakamoto Y, Akiyama M, Fujii C, Kondo T, Kobayashi K, Kaneko S, Mukaida N. Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine-induced murine liver fibrosis. Lab Invest 2002; 82: 571-583 [PMID: 12003998 DOI: 10.1038/labinvest. 3780452]
59. Zhang W, Kudo H, Kawai K, Fujisaka S, Usui I, Sugiyama T, Tsukada K, Chen N, Takahara T. Tumor necrosis factoralpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. Biochem Biophys Res Commun 2010; 391: 1731-1736 [PMID: 20043871 DOI: 10.1016/j.bbrc.2009.12.144]
60. Chavez-Tapia NC, Rosso N, Tiribelli C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol 2012; 12: 20 [PMID: 22380754 DOI: 10.1186/1471-230X-12-20]
61. Tsujimoto T, Kawaratani H, Kitazawa T, Uemura M, Fukui H. Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis. Dig Dis Sci 2012; 57: 1144-1151 [PMID: 22367065 DOI: 10.1007/s10620-012-2073-z]
62. Lucero D, Zago V, López GI, Graffigna M, Fainboim H, Miksztowicz V, Meroño T, Belli S, Levalle O, Wikinski R, Brites F, Berg G, Schreier L. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome. Clin Chim Acta 2011; 412: 143-147 [PMID: 20887718 DOI: 10.1016/j.cca.2010.09.025]
63. Lebensztejn DM, Kowalczuk D, Tarasów E, Skiba E, Kaczmarski M. Tumor necrosis factor alpha and its soluble receptors in obese children with NAFLD. Adv Med Sci 2010; 55: 74-79 [PMID: 20371430 DOI: 10.2478/v10039-010-0008-5]
64. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-421 [PMID: 18081738 DOI: 10.1111/j.1365-2036.2007.03586.x]
65. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22: 347-352 [PMID: 20410258 DOI: 10.1093/intimm/dxq030]
66. Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Roka R, Schernthaner G. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042-1047 [PMID: 12714437 DOI: 10.1161/01.ATV.0000073313.16135.21]
67. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-190 [PMID: 15685173 DOI: 10.1038/ nm1166]
68. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-419 [PMID: 12883485 DOI: 10.1053/jhep.2003.50316]
69. Tarantino G, Marra M, Contaldo F, Pasanisi F. Basal metabolic rate in morbidly obese patients with non-alcoholic fatty liver disease. Clin Invest Med 2008; 31: E24-E29 [PMID: 18312746]
70. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274: 1379-1383 [PMID: 8910279 DOI: 10.1126/science. 274.5291.1379]
71. El-Assal O, Hong F, Kim WH, Radaeva S, Gao B. IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol 2004; 1: 205-211 [PMID: 16219169]
72. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-1379 [PMID: 18510618 DOI: 10.1111/j.1572-0241.2007.01774.x]
73. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-783 [PMID: 16998510 DOI: 10.1038/nri1937]
74. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004; 4: 371-379 [PMID: 15122202]
75. Kolak M, Westerbacka J, Velagapudi VR, Wågsäter D, Yetukuri L, Makkonen J, Rissanen A, Häkkinen AM, Lindell M, Bergholm R, Hamsten A, Eriksson P, Fisher RM, Oresic M, Yki-Järvinen H. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007; 56: 1960-1968 [PMID: 17620421 DOI: 10.2337/db07-0111]
76. Procaccini C, Jirillo E, Matarese G. Leptin as an immunomodulator. Mol Aspects Med 2012; 33: 35-45 [PMID: 22040697]
77. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41: 943-949 [PMID: 15582127 DOI: 10.1016/j.jhep.2004.08.020]
78. Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, Pasanisi F, Contaldo F, Scopacasa F, Capone D. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med 2008; 6: 72 [PMID: 19038040 DOI: 10.1186/1479-5876-6-72]
79. den Boer MA, Voshol PJ, Schröder-van der Elst JP, Korsheninnikova E, Ouwens DM, Kuipers F, Havekes LM, Romijn JA. Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during highfat feeding in mice. Endocrinology 2006; 147: 4553-4558 [PMID: 16709607 DOI: 10.1210/en.2006-0417]
80. Mager DR, Yap J, Rodriguez-Dimitrescu C, Mazurak V, Ball G, Gilmour S. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease. Nutr Clin Pract 2013; 28: 101-111 [PMID: 23042833]
81. Cintra DE, Pauli JR, Araújo EP, Moraes JC, de Souza CT, Milanski M, Morari J, Gambero A, Saad MJ, Velloso LA. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol 2008; 48: 628-637 [PMID: 18267346 DOI: 10.1016/j.jhep.2007.12.017]
82. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palù G, Martines D. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G518-G525 [PMID: 17023554 DOI: 10.1152/ajpgi.00024.2006]
83. Kant P, Fazakerley R, Hull MA. Faecal calprotectin levels before and after weight loss in obese and overweight subjects. Int J Obes (Lond) 2013; 37: 317-319 [PMID: 22410961 DOI: 10.1038/ijo.2012.38]
84. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rotellar F, Valentí V, Silva C, Gil MJ, Fernández-Real JM, Salvador J, Frühbeck G. Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med 2011; 17: 1157-1167 [PMID: 21738950 DOI: 10.2119/molmed.2011.00144]
85. Mortensen OH, Nielsen AR, Erikstrup C, Plomgaard P, Fischer CP, Krogh-Madsen R, Lindegaard B, Petersen AM, Taudorf S, Pedersen BK. Calprotectin--a novel marker of obesity. PLoS One 2009; 4: e7419 [PMID: 19823685 DOI: 10.1371/journal.pone.0007419]
86. Furness JB, Kunze WA, Clerc N. Nutrient tasting and signaling mechanisms in the gut. II. The intestine as a sensory organ: neural, endocrine, and immune responses. Am J Physiol 1999; 277: G922-G928 [PMID: 10564096]
87. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-1294 [PMID: 16771951 DOI: 10.1111/j.1572-0241.2006.00672.x]
88. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-1783 [PMID: 12055584 DOI: 10.1053/gast.2002.33579]
89. Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400 [PMID: 19174797 DOI: 10.1038/ajg.2008.94]
90. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811 [PMID: 11076879 DOI: 10.1136/gut.47.6.804]
91. Ohman L, Isaksson S, Lundgren A, Simrén M, Sjövall H. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 980-986 [PMID: 16234043 DOI: 10.1016/S1542-3565]
92. Walker MM, Talley NJ, Prabhakar M, Pennaneac'h CJ, Aro P, Ronkainen J, Storskrubb T, Harmsen WS, Zinsmeister AR, Agreus L. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009; 29: 765-773 [PMID: 19183150]
93. Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008; 57: 923-929 [PMID: 18252749]
94. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702 [PMID: 14988823 DOI: 10.1053/j.gastro.2003.11.055]
95. Barbara G, Cremon C, Carini G, Bellacosa L, Zecchi L, De Giorgio R, Corinaldesi R, Stanghellini V. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil 2011; 17: 349-359 [PMID: 22148103 DOI: 10.5056/ jnm.2011.17.4.349]
96. Braak B, Klooker TK, Wouters MM, Welting O, van der Loos CM, Stanisor OI, van Diest S, van den Wijngaard RM, Boeckxstaens GE. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship? Am J Gastroenterol 2012; 107: 715-726 [PMID: 22488080 DOI: 10.1038/ajg.2012.54]
97. Motzer SA, Jarrett M, Heitkemper MM, Tsuji J. Natural killer cell function and psychological distress in women with and without irritable bowel syndrome. Biol Res Nurs 2002; 4: 31-42 [PMID: 12363280 DOI: 10.1177/1099800402004001005]
98. Kristjánsson G, Venge P, Wanders A, Lööf L, Hällgren R. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut 2004; 53: 1806-1812 [PMID: 15542519]
99. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-457 [PMID: 11012945 DOI: 10.1046/j.1365-2982.2000.00221.x]
100. Roth J, Vogl T, Sorg C, Sunderkötter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003; 24: 155-158 [PMID: 12697438 DOI: 10.1016/S1471-4906]
101. Grad C, David L, Portincasa P, Dumitraşcu DL. Diagnostic value of calprotectin in irritable bowel syndrome and in inflammatory bowel disease. Rom J Intern Med 2012; 50: 3-6 [PMID: 22788087]
102. Keohane J, O'Mahony C, O'Mahony L, O'Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010; 105: 1788, 1789-1794; quiz 1795 [PMID: 20389294 DOI: 10.1038/ajg.2010.156]
103. Shulman RJ, Eakin MN, Czyzewski DI, Jarrett M, Ou CN. Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome. J Pediatr 2008; 153: 646-650 [PMID: 18538790 DOI: 10.1016/j.jpeds.2008.04.062]
104. Ohman L, Isaksson S, Lindmark AC, Posserud I, Stotzer PO, Strid H, Sjövall H, Simrén M. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 1205-1212 [PMID: 19367268 DOI: 10.1038/ajg.2009.116]
105. Holmén N, Isaksson S, Simrén M, Sjövall H, Ohman L. CD4+CD25+ regulatory T cells in irritable bowel syndrome patients. Neurogastroenterol Motil 2007; 19: 119-125 [PMID: 17244166 DOI: 10.1111/j.1365-2982.2006.00878.x]
106. Andoh A, Ogawa A, Bamba S, Fujiyama Y. Interaction between interleukin-17-producing CD4+ T cells and colonic subepithelial myofibroblasts: what are they doing in mucosal inflammation? J Gastroenterol 2007; 42 Suppl 17: 29-33 [PMID: 17238023 DOI: 10.1007/s00535-006-1926-7]
107. Scalera A, Loguercio C. Focus on irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2012; 16: 1155-1171 [PMID: 23047498]
108. Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ, Holtmann G. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-920 [PMID: 17383420 DOI: 10.1053/j.gastro.2007.01.046]
109. Scully P, McKernan DP, Keohane J, Groeger D, Shanahan F, Dinan TG, Quigley EM. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010; 105: 2235-2243 [PMID: 20407431 DOI: 10.1038/ajg.2010.159]
110. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O' Mahony L, O'Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-311 [PMID: 16472586 DOI: 10.1053/j.gastro.2005.11.033]
111. Dinan TG, Clarke G, Quigley EM, Scott LV, Shanahan F, Cryan J, Cooney J, Keeling PW. Enhanced cholinergicmediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol 2008; 103: 2570-2576 [PMID: 18785949 DOI: 10.1111/j.1572-0241.2008.01871.x]
112. Schmulson M, Pulido-London D, Rodriguez O, Morales-Rochlin N, Martinez-García R, Gutierrez-Ruiz MC, López-Alvarenga JC, Robles-Díaz G, Gutiérrez-Reyes G. Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol 2012; 107: 747-753 [PMID: 22270083 DOI: 10.1038/ajg.2011.484]
113. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551 [PMID: 15765388 DOI: 10.1111/j.1365-2982.2012.01990.x]
114. Bashashati M, Rezaei N, Bashashati H, Shafieyoun A, Daryani NE, Sharkey KA, Storr M. Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 2012; 24: 1102-e566 [PMID: 22897390 DOI: 10.1111/ j.1365-2982.2012.01990.x]
115. O'Malley D, Liston M, Hyland NP, Dinan TG, Cryan JF. Colonic soluble mediators from the maternal separation model of irritable bowel syndrome activate submucosal neurons via an interleukin-6-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 2011; 300: G241-G252 [PMID: 21109592 DOI: 10.1152/ajpgi.00385.2010]
116. Macsharry J, O'Mahony L, Fanning A, Bairead E, Sherlock G, Tiesman J, Fulmer A, Kiely B, Dinan TG, Shanahan F, Quigley EM. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 1467-1476 [PMID: 18752146 DOI: 10.1080/00365520802276127]
117. Collins SM, McHugh K, Jacobson K, Khan I, Riddell R, Murase K, Weingarten HP. Previous inflammation alters the response of the rat colon to stress. Gastroenterology 1996; 111: 1509-1515 [PMID: 8942729 DOI: 10.1016/ S0016-5085(96)70012-4]
118. Sun X, Lan C, An Y, Sun Y. Colonic expression of Runx3 protein and TGF-β(1) and their correlation in patients with irritable bowel syndrome. Asian Pac J Trop Med 2011; 4: 547-549 [PMID: 21803306 DOI: 10.1016/S1995-7645(11)60143-0]
119. Chen J, Zhang Y, Deng Z. Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome. BMC Gastroenterol 2012; 12: 91 [PMID: 22816602 DOI: 10.1186/1471-230X-12-91]
120. Ortiz-Lucas M, Saz-Peiró P, Sebastián-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines. Rev Esp Enferm Dig 2010; 102: 711-717 [PMID: 21198313 DOI: 10.4321/S1130-01082010001200006]
121. Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523-526 [PMID: 12631663 DOI: 10.1136/gut.52.4.523]
122. Hughes PA, Harrington AM, Castro J, Liebregts T, Adam B, Grasby DJ, Isaacs NJ, Maldeniya L, Martin CM, Persson J, Andrews JM, Holtmann G, Blackshaw LA, Brierley SM. Sensory neuro-immune interactions differ between Irritable Bowel Syndrome subtypes. Gut 2012 Jul 27; Epub ahead of print [PMID: 22767422 DOI: 10.1136/gutjnl-2011-301856]
123. Mizutani T, Akiho H, Khan WI, Murao H, Ogino H, Kanayama K, Nakamura K, Takayanagi R. Persistent gut motor dysfunction in a murine model of T-cell-induced enteropathy. Neurogastroenterol Motil 2010; 22: 196-203, e65 [PMID: 19735478]
124. Kindt S, Van Oudenhove L, Broekaert D, Kasran A, Ceuppens JL, Bossuyt X, Fischler B, Tack J. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009; 21: 389-398 [PMID: 19126184 DOI: 10.1111/j.1365-2982.2008.01220.x]
125. Hermann GE, Holmes GM, Rogers RC. TNF(alpha) modulation of visceral and spinal sensory processing. Curr Pharm Des 2005; 11: 1391-1409 [PMID: 15853670 DOI: 10.2174/1381 612053507828]
126. Hermann GE, Rogers RC. TNFalpha: a trigger of autonomic dysfunction. Neuroscientist 2008; 14: 53-67 [PMID: 17911224 DOI: 10.1177/1073858407305725]
127. O'Malley D, Dinan TG, Cryan JF. Altered expression and secretion of colonic interleukin-6 in a stress-sensitive animal model of brain-gut axis dysfunction. J Neuroimmunol 2011; 235: 48-55 [PMID: 21565410 DOI: 10.1016/ j.jneuroim.2011.04.003]
128. McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1045-1052 [PMID: 21453321 DOI: 10.1111/j.1365-2036.2011.04624.x]
129. Al-Sadi R, Boivin M, Ma T. Mechanism of cytokine modulation of epithelial tight junction barrier. Front Biosci (Landmark Ed) 2009; 14: 2765-2778 [PMID: 19273235 DOI: 10.2741/3413]
130. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, Krakoff J. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011; 94: 58-65 [PMID: 21543530 DOI: 10.3945/ajcn.110.010132]
131. Ashida H, Ogawa M, Kim M, Mimuro H, Sasakawa C. Bacteria and host interactions in the gut epithelial barrier. Nat Chem Biol 2012; 8: 36-45 [PMID: 22173358 DOI: 10.1038/ nchembio.741]
132. Tappenden KA, Deutsch AS. The physiological relevance of the intestinal microbiota--contributions to human health. J Am Coll Nutr 2007; 26: 679S-683S [PMID: 18187433]
133. Gigante G, Tortora A, Ianiro G, Ojetti V, Purchiaroni F, Campanale M, Cesario V, Scarpellini E, Gasbarrini A. Role of gut microbiota in food tolerance and allergies. Dig Dis 2011; 29: 540-549 [PMID: 22179209 DOI: 10.1159/000332977]
134. Fukata M, Vamadevan AS, Abreu MT. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol 2009; 21: 242-253 [PMID: 19748439 DOI: 10.1016/j.smim.2009.06.005]
135. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology 2008; 48: 670-678 [PMID: 18666225 DOI: 10.1002/hep.22399]
136. Rodríguez-Fandiño O, Hernández-Ruiz J, Schmulson M. From cytokines to toll-like receptors and beyond-current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil 2010; 16: 363-373 [PMID: 21103418 DOI: 10.5056/jnm.2010.16.4.363]
137. Miura K, Seki E, Ohnishi H, Brenner DA. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease. Gastroenterol Res Pract 2010; 2010: 362847 [PMID: 21274430]
138. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 2010; 10: 131-144 [PMID: 20098461 DOI: 10.1038/nri2707]
139. Ohman L, Lindmark AC, Isaksson S, Posserud I, Strid H, Sjövall H, Simrén M. Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients. Eur J Gastroenterol Hepatol 2012; 24: 398-405 [PMID: 22273988]
140. McKernan DP, Nolan A, Brint EK, O'Mahony SM, Hyland NP, Cryan JF, Dinan TG. Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome. PLoS One 2009; 4: e8226 [PMID: 20011045 DOI: 10.1371/journal. pone.0008226]
141. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106: 329-336 [PMID: 21102570 DOI: 10.1038/ajg.2010.438]
142. Jin B, Sun T, Yu XH, Yang YX, Yeo AE. The effects of TLR activation on T-cell development and differentiation. Clin Dev Immunol 2012; 2012: 836485 [PMID: 22737174 DOI: 10.1155/2012/836485]
143. Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, Littman DR, Benoist C, Mathis D. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010; 32: 815-827 [PMID: 20620945 DOI: 10.1016/j.immuni.2010.06.001]
144. Ather JL, Ckless K, Martin R, Foley KL, Suratt BT, Boyson JE, Fitzgerald KA, Flavell RA, Eisenbarth SC, Poynter ME. Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol 2011; 187: 64-73 [PMID: 21622869 DOI: 10.4049/jimmunol.1100500]
145. Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, Yagita H, Ishii N, Evans R, Honda K, Takeda K. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008; 455: 808-812 [PMID: 18716618 DOI: 10.1038/nature07240]
146. Zaph C, Du Y, Saenz SA, Nair MG, Perrigoue JG, Taylor BC, Troy AE, Kobuley DE, Kastelein RA, Cua DJ, Yu Y, Artis D. Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. J Exp Med 2008; 205: 2191-2198 [PMID: 18762568 DOI: 10.1084/jem.20080720]
147. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023 [PMID: 17183309 DOI: 10.1038/4441022a]
148. Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol 2009; 587: 4153-4158 [PMID: 19491241 DOI: 10.1113/jphysiol.2009.174136]
149. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 15718-15723 [PMID: 15505215 DOI: 10.1073/pnas.0407076101]
150. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031 [PMID: 17183312 DOI: 10.1038/nature05414]
151. Ilan Y. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol 2012; 18: 2609-2618 [PMID: 22690069 DOI: 10.3748/wjg.v18. i21.2609]
152. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772 [PMID: 17456850 DOI: 10.2337/db06-1491]
153. de Wit N, Derrien M, Bosch-Vermeulen H, Oosterink E, Keshtkar S, Duval C, de Vogel-van den Bosch J, Kleerebezem M, Müller M, van der Meer R. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am J Physiol Gastrointest Liver Physiol 2012; 303: G589-G599 [PMID: 22700822 DOI: 10.1152/ajpgi. 00488.2011]
154. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011; 140: 976-986 [PMID: 21129376 DOI: 10.1053/j.gastro.2010.11.049]
155. Collins SM, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis 2009; 41: 850-853 [PMID: 19740713 DOI: 10.1016/j.dld.2009.07.023]
156. Husebye E, Hellström PM, Midtvedt T. Intestinal microflora stimulates myoelectric activity of rat small intestine by pro-moting cyclic initiation and aboral propagation of migrating myoelectric complex. Dig Dis Sci 1994; 39: 946-956 [PMID: 8174436 DOI: 10.1007/BF02087542]
157. Bär F, Von Koschitzky H, Roblick U, Bruch HP, Schulze L, Sonnenborn U, Böttner M, Wedel T. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol Motil 2009; 21: 559-566, e16-17 [PMID: 19220758]
158. Guarino MP, Altomare A, Stasi E, Marignani M, Severi C, Alloni R, Dicuonzo G, Morelli L, Coppola R, Cicala M. Effect of acute mucosal exposure to Lactobacillus rhamnosus GG on human colonic smooth muscle cells. J Clin Gastroenterol 2008; 42 Suppl 3 Pt 2: S185-S190 [PMID: 18685510 DOI: 10.1097/MCG.0b013e31817e1cac]
159. Kamiya T, Wang L, Forsythe P, Goettsche G, Mao Y, Wang Y, Tougas G, Bienenstock J. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 2006; 55: 191-196 [PMID: 16361309 DOI: 10.1136/gut.2005.070987]
160. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5: 185-194 [PMID: 7121297]
161. Wyatt GM, Bayliss CE, Lakey AF, Bradley HK, Hunter JO, Jones VA. The faecal flora of two patients with food-related irritable bowel syndrome during challenge with symptomprovoking foods. J Med Microbiol 1988; 26: 295-299 [PMID: 3398034 DOI: 10.1099/00222615-26-4-295]
162. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62: 159-176 [PMID: 22730468]
163. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 1279-1286 [PMID: 19602448 DOI: 10.1016/ j.cgh.2009.06.031]
164. Ghoshal UC, Kumar S, Mehrotra M, Lakshmi C, Misra A. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic nonspecific diarrhea. J Neurogastroenterol Motil 2010; 16: 40-46 [PMID: 20535325 DOI: 10.5056/jnm.2010.16.1.40]
165. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of postinfectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535-544 [PMID: 17661757]
166. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001; 2: 285-293 [PMID: 11283726 DOI: 10.1038/35067088]
167. Farquhar MG, Palade GE. Junctional complexes in various epithelia. J Cell Biol 1963; 17: 375-412 [PMID: 13944428 DOI: 10.1083/jcb.17.2.375]
168. Förster C. Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol 2008; 130: 55-70 [PMID: 18415116 DOI: 10.1007/s00418-008-0424-9]
169. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009; 124: 3-20; quiz 21-22 [PMID: 19560575 DOI: 10.1016/j.jaci.2009.05.038]
170. Chen ML, Pothoulakis C, LaMont JT. Protein kinase C signaling regulates ZO-1 translocation and increased paracellular flux of T84 colonocytes exposed to Clostridium difficile toxin A. J Biol Chem 2002; 277: 4247-4254 [PMID: 11729192 DOI: 10.1074/jbc.M109254200]
171. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003; 171: 6164-6172 [PMID: 14634132]
172. Suzuki T, Yoshinaga N, Tanabe S. Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J Biol Chem 2011; 286: 31263-31271 [PMID: 21771795 DOI: 10.1074/jbc.M111.238147]
173. Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G, Del Vecchio Blanco C, Loguercio C. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis 2011; 43: 431-438 [PMID: 21163715 DOI: 10.1016/j.dld.2010.10.015]
174. Sabaté JM, Jouët P, Harnois F, Mechler C, Msika S, Grossin M, Coffin B. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 2008; 18: 371-377 [PMID: 18286348 DOI: 10.1007/s11695-007-9398-2]
175. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-211 [PMID: 11156641 DOI: 10.1136/gut.48.2.206]
176. Spruss A, Kanuri G, Stahl C, Bischoff SC, Bergheim I. Metformin protects against the development of fructoseinduced steatosis in mice: role of the intestinal barrier function. Lab Invest 2012; 92: 1020-1032 [PMID: 22525431 DOI: 10.1038/labinvest.2012.75]
177. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887 [PMID: 19291785 DOI: 10.1002/hep.22848]
178. Shanab AA, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F, Gazareen S, Murphy E, Quigley EM. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011; 56: 1524-1534 [PMID: 21046243 DOI: 10.1007/s10620-010-1447-3]
179. Bellot P, Francés R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013; 33: 31-39 [PMID: 23121656 DOI: 10.1111/liv.12021]
180. Sakaguchi S, Takahashi S, Sasaki T, Kumagai T, Nagata K. Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress. Drug Metab Pharmacokinet 2011; 26: 30-46 [PMID: 21150132 DOI: 10.2133/dmpk.DMPK-10-RV-087]
181. Ruiz AG, Casafont F, Crespo J, Cayón A, Mayorga M, Estebanez A, Fernadez-Escalante JC, Pons-Romero F. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of nonalcoholic steatohepatitis. Obes Surg 2007; 17: 1374-1380 [PMID: 18000721 DOI: 10.1007/s11695-007-9243-7]
182. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091-1103 [PMID: 19240062 DOI: 10.1136/ gut.2008.165886]
183. Lam YY, Ha CW, Campbell CR, Mitchell AJ, Dinudom A, Oscarsson J, Cook DI, Hunt NH, Caterson ID, Holmes AJ, Storlien LH. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One 2012; 7: e34233 [PMID: 22457829 DOI: 10.1371/journal. pone.0034233]
184. Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol 2009; 15: 3591-3596 [PMID: 19653335 DOI: 10.3748/wjg.15.3591]
185. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-173 [PMID: 20101257 DOI: 10.1038/nrgastro.2010.4]
186. Róka R, Rosztóczy A, Leveque M, Izbéki F, Nagy F, Molnár T, Lonovics J, Garcia-Villar R, Fioramonti J, Wittmann T, Bueno L. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5: 550-555 [PMID: 17336590 DOI: 10.1016/j.cgh.2006.12.004]
187. Martínez C, Vicario M, Ramos L, Lobo B, Mosquera JL, Alonso C, Sánchez A, Guilarte M, Antolín M, de Torres I, González-Castro AM, Pigrau M, Saperas E, Azpiroz F, Santos J. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol 2012; 107: 736-746 [PMID: 22415197 DOI: 10.1038/ajg.2011.472]
188. Kong WM, Gong J, Dong L, Xu JR. Changes of tight junction claudin-1,-3,-4 protein expression in the intestinal mucosa in patients with irritable bowel syndrome. Nanfang Yike Daxue Xuebao 2007; 27: 1345-1347 [PMID: 17884774]
189. Khan WI, Collins SM. Gut motor function: immunological control in enteric infection and inflammation. Clin Exp Immunol 2006; 143: 389-397 [PMID: 16487236 DOI: 10.1111/ j.1365-2249.2005.02979.x]
190. Vallance BA, Blennerhassett PA, Collins SM. Increased intestinal muscle contractility and worm expulsion in nematode-infected mice. Am J Physiol 1997; 272: G321-G327 [PMID: 9124356]
191. Vallance BA, Galeazzi F, Collins SM, Snider DP. CD4 T cells and major histocompatibility complex class II expression influence worm expulsion and increased intestinal muscle contraction during Trichinella spiralis infection. Infect Immun 1999; 67: 6090-6097 [PMID: 10531271]
192. Akiho H, Ihara E, Motomura Y, Nakamura K. Cytokineinduced alterations of gastrointestinal motility in gastrointestinal disorders. World J Gastrointest Pathophysiol 2011; 2: 72-81 [PMID: 22013552 DOI: 10.4291/wjgp.v2.i5.72]
193. Mannon P, Reinisch W. Interleukin 13 and its role in gut defence and inflammation. Gut 2012; 61: 1765-1773 [PMID: 22942239 DOI: 10.1136/gutjnl-2012-303461]
194. Sharkey KA, Mawe GM. Neuroimmune and epithelial interactions in intestinal inflammation. Curr Opin Pharmacol 2002; 2: 669-677 [PMID: 12482729 DOI: 10.1016/S1471-4892]
195. Motomura Y, Ghia JE, Wang H, Akiho H, El-Sharkawy RT, Collins M, Wan Y, McLaughlin JT, Khan WI. Enterochromaffin cell and 5-hydroxytryptamine responses to the same infectious agent differ in Th1 and Th2 dominant environments. Gut 2008; 57: 475-481 [PMID: 18198200 DOI: 10.1136/ gut.2007.129296]
196. Chen JX, Pan H, Rothman TP, Wade PR, Gershon MD. Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am J Physiol 1998; 275: G433-G448 [PMID: 9724254]
197. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996; 16: 2352-2364 [PMID: 8601815]
198. Li J, Ma W, Wang S. Slower gastric emptying in high-fat diet induced obese rats is associated with attenuated plasma ghrelin and elevated plasma leptin and cholecystokinin concentrations. Regul Pept 2011; 171: 53-57 [PMID: 21784108 DOI: 10.1016/j.regpep.2011.07.004]
199. Covasa M, Ritter RC. Adaptation to high-fat diet reduces inhibition of gastric emptying by CCK and intestinal oleate. Am J Physiol Regul Integr Comp Physiol 2000; 278: R166-R170 [PMID: 10644635]
200. Suzuki S, Ramos EJ, Goncalves CG, Chen C, Meguid MM. Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model. Surgery 2005; 138: 283-290 [PMID: 16153438 DOI: 10.1016/j.surg.2005.05.013]
201. Hyland NP, Rybicka JM, Ho W, Pittman QJ, Macnaughton WK, Sharkey KA. Adaptation of intestinal secretomotor function and nutrient absorption in response to dietinduced obesity. Neurogastroenterol Motil 2010; 22: 602-e171 [PMID: 20426798 DOI: 10.1111/j.1365-2982.2010.01504.x]
202. Fornari F, Callegari-Jacques SM, Dantas RO, Scarsi AL, Ruas LO, de Barros SG. Obese patients have stronger peristalsis and increased acid exposure in the esophagus. Dig Dis Sci 2011; 56: 1420-1426 [PMID: 20972851 DOI: 10.1007/ s10620-010-1454-4]
203. Little TJ, Horowitz M, Feinle-Bisset C. Modulation by highfat diets of gastrointestinal function and hormones associated with the regulation of energy intake: implications for the pathophysiology of obesity. Am J Clin Nutr 2007; 86: 531-541 [PMID: 17823414]
204. Vazquez Roque MI, Camilleri M, Stephens DA, Jensen MD, Burton DD, Baxter KL, Zinsmeister AR. Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Gastroenterology 2006; 131: 1717-1724 [PMID: 17087952 DOI: 10.1053/j.gastro.2006.10.025]
205. Di Ciaula A, Wang DQ, Portincasa P. Gallbladder and gastric motility in obese newborns, pre-adolescents and adults. J Gastroenterol Hepatol 2012; 27: 1298-1305 [PMID: 22497555 DOI: 10.1111/j.1440-1746.2012.07149.x]
206. Xing J, Chen JD. Alterations of gastrointestinal motility in obesity. Obes Res 2004; 12: 1723-1732 [PMID: 15601965 DOI: 10.1038/oby.2004.213]
207. Madrid AM, Poniachik J, Quera R, Defilippi C. Small intestinal clustered contractions and bacterial overgrowth: a frequent finding in obese patients. Dig Dis Sci 2011; 56: 155-160 [PMID: 20431947 DOI: 10.1007/s10620-010-1239-9]
208. Lata J, Jurankova J, Kopacova M, Vitek P. Probiotics in hepatology. World J Gastroenterol 2011; 17: 2890-2896 [PMID: 21734800 DOI: 10.3748/wjg.v17.i24.2890]
209. Soza A, Riquelme A, González R, Alvarez M, Pérez-Ayuso RM, Glasinovic JC, Arrese M. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2005; 50: 1136-1140 [PMID: 15986870 DOI: 10.1007/ s10620-005-2720-8]
210. Nagasako CK, de Oliveira Figueiredo MJ, de Souza Almeida JR, Lorena SL, Akasaka HM, Pavan CR, Yamanaka A, Pereira TS, Soares EC, Mesquita MA. Investigation of autonomic function and orocecal transit time in patients with nonalcoholic cirrhosis and the potential influence of these factors on disease outcome. J Clin Gastroenterol 2009; 43: 884-889 [PMID: 19295446 DOI: 10.1097/ MCG.0b013e31818de34c]
211. Haub S, Ritze Y, Ladel I, Saum K, Hubert A, Spruss A, Trautwein C, Bischoff SC. Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice. J Pharmacol Exp Ther 2011; 339: 790-798 [PMID: 21903748 DOI: 10.1124/jpet.111.181834]
212. Haub S, Kanuri G, Volynets V, Brune T, Bischoff SC, Bergheim I. Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. Am J Physiol Gastrointest Liver Physiol 2010; 298: G335-G344 [PMID: 19713474 DOI: 10.1152/ajpgi.00088.2009]
213. Corsetti M, Caenepeel P, Fischler B, Janssens J, Tack J. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol 2004; 99: 1152-1159 [PMID: 15180740 DOI: 10.1111/j.1572-0241.2004.30040.x]
214. Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003; 98: 783-788 [PMID: 12738456 DOI: 10.1111/ j.1572-0241.2003.07389.x]
215. Evans PR, Bak YT, Shuter B, Hoschl R, Kellow JE. Gastroparesis and small bowel dysmotility in irritable bowel syndrome. Dig Dis Sci 1997; 42: 2087-2093 [PMID: 9365140]
216. Gunnarsson J, Simrén M. Peripheral factors in the pathophysiology of irritable bowel syndrome. Dig Liver Dis 2009; 41: 788-793 [PMID: 19665956 DOI: 10.1016/j.dld.2009.07.006]
217. Larsson MH, Simrén M, Thomas EA, Bornstein JC, Lindström E, Sjövall H. Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 812-820 [PMID: 17883433 DOI: 10.1111/j.1365-2982.2007.00941.x]
218. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987; 92: 1885-1893 [PMID: 3569764]
219. Kellow JE, Eckersley GM, Jones M. Enteric and central contributions to intestinal dysmotility in irritable bowel syndrome. Dig Dis Sci 1992; 37: 168-174 [PMID: 1735331 DOI: 10.1007/BF01308167]
220. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-1659 [PMID: 14724817 DOI: 10.1053/j.gastro.2003.09.028]
221. Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008; 23: 1689-1694 [PMID: 19120860 DOI: 10.1111/j.1440-1746.2008.05574.x]
222. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-357 [PMID: 15822040 DOI: 10.1016/S1542-3565]
223. Spiller R, Garsed K. Infection, inflammation, and the irritable bowel syndrome. Dig Liver Dis 2009; 41: 844-849 [PMID: 19716778 DOI: 10.1016/j.dld.2009.07.007]
224. Moses PL, Bannon C, Linden DR, Crowell MD, Sharkey KA, Mawe GM. Evidence for altered serotonin signalling in IBD and constipation predominant IBS. Amer J Gastroenterol 2002; 97: S274 [DOI:10.1016/S0002-9270(02)05317-0]
225. Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE, McKinzie S, Urrutia R. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123: 425-432 [PMID: 12145795 DOI: 10.1053/gast.2002.34780]
226. Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, Stanghellini V, Grundy D, Tonini M, De Ponti F, Corinaldesi R, Barbara G. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011; 106: 1290-1298 [PMID: 21427712 DOI: 10.1038/ajg.2011.86]
227. Anitha M, Vijay-Kumar M, Sitaraman SV, Gewirtz AT, Srinivasan S. Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. Gastroenterology 2012; 143: 1006-16. e4 [PMID: 22732731 DOI: 10.1053/j.gastro.2012.06.034]
228. Tattoli I, Petitta C, Scirocco A, Ammoscato F, Cicenia A, Severi C. Microbiota, innate immune system, and gastrointestinal muscle: ongoing studies. J Clin Gastroenterol 2012; 46 Suppl: S6-11 [PMID: 22955360 DOI: 10.1097/ MCG.0b013e318265ea7d]
229. Quigley EM. Microflora modulation of motility. J Neurogastroenterol Motil 2011; 17: 140-147 [PMID: 21602990 DOI: 10.5056/jnm.2011.17.2.140]
230. Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 2002; 47: 2639-2643 [PMID: 12498278]
231. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011; 130: 226-238 [PMID: 21334376 DOI: 10.1016/j.pharmth era.2011.01.014]
232. Kim DY, Camilleri M. Serotonin: a mediator of the braingut connection. Am J Gastroenterol 2000; 95: 2698-2709 [PMID: 11051338]
233. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 2009; 136: 2003-2014 [PMID: 19457424 DOI: 10.1053/ j.gastro.2009.01.075]
234. Stasi C, Rosselli M, Bellini M, Laffi G, Milani S. Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol 2012; 47: 1177-1185 [PMID: 22766747 DOI: 10.1007/ s00535-012-0627-7]
235. Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann N Y Acad Sci 2006; 1083: 77-110 [PMID: 17148735 DOI: 10.1196/annals.1367.008]
236. Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 2005; 11: 963-972 [PMID: 15777247 DOI: 10.2174/1381612053381701]
237. Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab JP, Zajecka JM, Bruno CJ, Henderson MA, Reinus JF, Evans DL, Asnis GM, Miller AH. Paroxetine for prevention of depressive symptoms induced by interferonalpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007; 25: 1163-1174 [PMID: 17451562 DOI: 10.1111/ j.1365-2036.2007.03316.x]
238. De Souza CT, Araujo EP, Bordin S, Ashimine R, Zollner RL, Boschero AC, Saad MJ, Velloso LA. Consumption of a fatrich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology 2005; 146: 4192-4199 [PMID: 16002529 DOI: 10.1210/en.2004-1520]
239. Zhang X, Dong F, Ren J, Driscoll MJ, Culver B. High dietary fat induces NADPH oxidase-associated oxidative stress and inflammation in rat cerebral cortex. Exp Neurol 2005; 191: 318-325 [PMID: 15649487 DOI: 10.1016/j.expneurol.2004.10.011]
240. Bilbo SD, Tsang V. Enduring consequences of maternal obesity for brain inflammation and behavior of offspring. FASEB J 2010; 24: 2104-2115 [PMID: 20124437 DOI: 10.1096/ fj.09-144014]
241. Ghareeb DA, Hafez HS, Hussien HM, Kabapy NF. Nonalcoholic fatty liver induces insulin resistance and metabolic disorders with development of brain damage and dysfunction. Metab Brain Dis 2011; 26: 253-267 [PMID: 21881966 DOI: 10.1007/s11011-011-9261-y]
242. Faith MS, Butryn M, Wadden TA, Fabricatore A, Nguyen AM, Heymsfield SB. Evidence for prospective associations among depression and obesity in population-based studies. Obes Rev 2011; 12: e438-e453 [PMID: 21414128 DOI: 10.1111/ j.1467-789X.2010.00843.x]
243. Herrera-Marquez R, Hernandez-Rodriguez J, Medina-Serrano J, Boyzo-Montes de Oca A, Manjarrez-Gutierrez G. Association of metabolic syndrome with reduced central serotonergic activity. Metab Brain Dis 2011; 26: 29-35 [PMID: 21181433 DOI: 10.1007/s11011-010-9229-3]
244. Tarantino G, Savastano S, Colao A, Polichetti G, Capone D. Urinary excretion of 5-hydroxy-3-indoleacetic acid in dystimic/depressed, adult obese women: what correlations to hepatic steatosis? Int J Immunopathol Pharmacol 2011; 24: 769-779 [PMID: 21978708]
245. Bose M, Oliván B, Laferrère B. Stress and obesity: the role of the hypothalamic-pituitary-adrenal axis in metabolic disease. Curr Opin Endocrinol Diabetes Obes 2009; 16: 340-346 [PMID: 19584720 DOI: 10.1097/MED.0b013e32832fa137]
246. Targher G, Bertolini L, Rodella S, Zoppini G, Zenari L, Falezza G. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006; 64: 337-341 [PMID: 16487446 DOI: 10.1111/j.1365-2265.2006.02466.x]
247. Holt HB, Wild SH, Postle AD, Zhang J, Koster G, Umpleby M, Shojaee-Moradie F, Dewbury K, Wood PJ, Phillips DI, Byrne CD. Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men. Diabetologia 2007; 50: 1024-1032 [PMID: 17370058 DOI: 10.1007/s00125-007-0629-9]
248. Tomlinson JW, Moore J, Cooper MS, Bujalska I, Shahmanesh M, Burt C, Strain A, Hewison M, Stewart PM. Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 2001; 142: 1982-1989 [PMID: 11316764 DOI: 10.1210/en.142.5.1982]
249. Kaufman D, Banerji MA, Shorman I, Smith EL, Coplan JD, Rosenblum LA, Kral JG. Early-life stress and the development of obesity and insulin resistance in juvenile bonnet macaques. Diabetes 2007; 56: 1382-1386 [PMID: 17470564 DOI: 10.2337/db06-1409]
250. Fichna J, Storr MA. Brain-Gut Interactions in IBS. Front Pharmacol 2012; 3: 127 [PMID: 22783191 DOI: 10.3389/ fphar.2012.00127]
251. Clarke G, Fitzgerald P, Cryan JF, Cassidy EM, Quigley EM, Dinan TG. Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol 2009; 9: 6 [PMID: 19154614 DOI: 10.1186/1471-230X-9-6]
252. Clarke G, McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. A Distinct Profile of Tryptophan Metabolism along the Kynurenine Pathway Downstream of Toll-Like Receptor Activation in Irritable Bowel Syndrome. Front Pharmacol 2012; 3: 90 [PMID: 22661947 DOI: 10.3389/ fphar.2012.00090]
253. Piche T, Saint-Paul MC, Dainese R, Marine-Barjoan E, Iannelli A, Montoya ML, Peyron JF, Czerucka D, Cherikh F, Filippi J, Tran A, Hébuterne X. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008; 57: 468-473 [PMID: 18194987 DOI: 10.1136/gut.2007.127068]
254. Tarantino G, Finelli C, Colao A, Capone D, Tarantino M, Grimaldi E, Chianese D, Gioia S, Pasanisi F, Contaldo F, Scopacasa F, Savastano S. Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyltransferase? J Transl Med 2012; 10: 50 [PMID: 22424154 DOI: 10.1186/1479-5876-10-50]